SCHEMBL3984263

SCHEMBL3984263

CCc1ccc(NS(=O)(=O)c2cc(F)ccc2C)c(C(=O)O)c1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 8/20 0.71
▸ SLC16A3 O15427 1/20 0.53
▸ ALDH1A1 P00352 4/20 0.48
▸ HPGD P15428 3/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ MEP1B Q16820 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ MCL1 Q07820 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ USP2 O75604 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ BRD4 O60885 1/20 0.44
▸ ACLY P53396 1/20 0.43
▸ IDH1 O75874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3981557 0.88 METAP2 (0.64) METAP2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL3987881 0.85 METAP2 (0.69) METAP2ALDH1A1HPGDMEN1USP2
SCHEMBL3984413 0.83 METAP2 (1.00) METAP2ALDH1A1KDM4E
SCHEMBL3981500 0.81 METAP2 (0.71) METAP2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL3981388 0.80 METAP2 (0.77) METAP2ALDH1A1HSD17B10MCL1MEN1
SCHEMBL3981554 0.78 METAP2 (0.63) METAP2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3983978 0.77 METAP2 (0.73) METAP2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL3980105 0.77 METAP2 (0.81) METAP2ALDH1A1KDM4EMCL1
SCHEMBL3979169 0.76 METAP2 (1.00) METAP2ALDH1A1KDM4EMCL1MEN1
SCHEMBL3986786 0.76 METAP2 (0.71) METAP2ALDH1A1HPGDHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 — — US claimed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 — — US disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 — — US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 — — US disclosed
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885SLC16A3 929/4885ALDH1A1 3463/4885
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885SLC16A3 929/4885ALDH1A1 3463/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885SLC16A3 929/4885ALDH1A1 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback